Quantcast

Antibiotics biotech Iterum Therapeutics files for a $92 million IPO


Shutterstock photo

Iterum Therapeutics, which is developing oral and IV antibiotics for urinary tract infections and intra-abdominal infections, filed on Tuesday with the SEC to raise up to $92 million in an initial public offering.

The Dublin, Ireland-based company was founded in 2015 and booked $0.5 million in revenue for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol ITRM. Iterum Therapeutics filed confidentially on February 2, 2018. Leerink Partners and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.

The article Antibiotics biotech Iterum Therapeutics files for a $92 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?